An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
Timothy Daly, Karl Herrup, Alberto J. Espay
Abstract
Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer's Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.
Topics & Concepts
Argument (complex analysis)DiseasePsychologyAmyloid βAmyloid (mycology)Alzheimer's diseasePsychotherapistNeuroscienceEpistemologyMedicinePhilosophyInternal medicinePathologyAlzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchPharmacological Effects and Toxicity Studies